Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients

Background: Anemia-associated chronic kidney disease increases in more advanced stages with a subsequent acceleration in renal impairment progressing to end-stage renal disease. Although hepcidin and erythroferrone have been described as novel biomarkers of iron metabolism, there is still an area of...

Full description

Bibliographic Details

Published in:	Hematology, Transfusion and Cell Therapy
Main Authors:	Salwa Bakr, Karem Mohamed Salem, Ahmed Mohammed Rashed, Mohamed E A Tantawy, Asmaa Younis Elsary, Hanan Abdelmoneam Shamardl, Eman Mahmoud Ezzat
Format:	Article
Language:	English
Published:	Elsevier 2024-11-01
Subjects:	Anemia ESRD Hepcidin Erythroferrone Reticulocyte hemoglobin content Erythropoiesis-stimulating agent
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137924003006